In support of this idea, exogenous VEGF treatment prevents TGF-β-induced EndoMT during cardiac fibrosis (Illigens et al., 2017) and VEGFR2 expression is reduced in glioblastoma vessels alongside EndoMT program activation and acquired mesenchymal marker expression (Liu et al., 2018). This evidence concerns the gene KDR and glioblastoma.